Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Videos|September 23, 2026
An Uncharted Path: How Clinicians are Implementing Artificial Intelligence Across Cardiology
Fact checked by: Ryan Livingston
As AI continues to evolve at a breakneck pace, catch up on some of the ways it’s already been implemented in cardiovascular care.
Advertisement
Advertisement
Artificial intelligence (AI) is a burgeoning industry, evolving in practically every direction as it continues to develop. AI-based algorithms are being implemented in countless fields, medicine not least among them.
Related to this article
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Advertisement
Advertisement